{"date":"2025-07-18","count":19,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4138-2025-07-18-1850-d00cax","company_id":"4138","company":"曜亞","market":"上櫃","industry":"生技醫療","date":"2025-07-18","time":"18:50:28","subject":"代重要子公司曜亞國際(香港)有限公司公告法人董事改派代表人","clause":"第6款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：曜亞（4138），2025-07-18 18:50，「代重要子公司曜亞國際(香港)有限公司公告法人董事改派代表人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4743-2025-07-18-1742-x9115p","company_id":"4743","company":"合一","market":"上櫃","industry":"生技醫療","date":"2025-07-18","time":"17:42:01","subject":"公告本公司糖尿病足部傷口潰瘍新藥Fespixon (「速必一」)查驗登記，今日獲印尼食品與藥物管理局(BPOM)核發藥證","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：合一（4743），2025-07-18 17:42，「公告本公司糖尿病足部傷口潰瘍新藥Fespixon (「速必一」)查驗登記，今日獲印尼食品與藥物管理局(BPOM)核發藥證」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7724-2025-07-18-1728-1bkm0mx","company_id":"7724","company":"諾亞克","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"17:28:30","subject":"公告本公司代理發言人異動","clause":"第11款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：諾亞克（7724），2025-07-18 17:28，「公告本公司代理發言人異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7724-2025-07-18-1728-jeajve","company_id":"7724","company":"諾亞克","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"17:28:04","subject":"代重要子公司建齊股份有限公司公告總經理異動案","clause":"第6款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：諾亞克（7724），2025-07-18 17:28，「代重要子公司建齊股份有限公司公告總經理異動案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7724-2025-07-18-1727-19bpb7c","company_id":"7724","company":"諾亞克","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"17:27:23","subject":"代重要子公司卓和企業(股)公司公告總經理異動案","clause":"第6款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：諾亞克（7724），2025-07-18 17:27，「代重要子公司卓和企業(股)公司公告總經理異動案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7724-2025-07-18-1726-p67uuk","company_id":"7724","company":"諾亞克","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"17:26:31","subject":"公告本公司內部稽核主管異動","clause":"第11款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：諾亞克（7724），2025-07-18 17:26，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7724-2025-07-18-1725-l7qirp","company_id":"7724","company":"諾亞克","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"17:25:46","subject":"公告本公司會計主管異動","clause":"第11款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：諾亞克（7724），2025-07-18 17:25，「公告本公司會計主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7724-2025-07-18-1725-1ur6s63","company_id":"7724","company":"諾亞克","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"17:25:06","subject":"公告本公司財務長異動","clause":"第11款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：諾亞克（7724），2025-07-18 17:25，「公告本公司財務長異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7832-2025-07-18-1548-rzgerl","company_id":"7832","company":"智新生技*","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"15:48:02","subject":"公告本公司成立審計委員會，監察人自然解任","clause":"第6款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：智新生技*（7832），2025-07-18 15:48，「公告本公司成立審計委員會，監察人自然解任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7832-2025-07-18-1547-emmmmu","company_id":"7832","company":"智新生技*","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"15:47:33","subject":"公告本公司成立審計委員會及第一屆審計委員名單","clause":"第6款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：智新生技*（7832），2025-07-18 15:47，「公告本公司成立審計委員會及第一屆審計委員名單」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7832-2025-07-18-1546-7an535","company_id":"7832","company":"智新生技*","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"15:46:12","subject":"公告本公司114年第一次股東臨時會通過解除獨立董事競業禁止限制案","clause":"第22款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：智新生技*（7832），2025-07-18 15:46，「公告本公司114年第一次股東臨時會通過解除獨立董事競業禁止限制案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7832-2025-07-18-1545-1frxnbc","company_id":"7832","company":"智新生技*","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"15:45:28","subject":"公告本公司114年第一次股東臨時會獨立董事當選名單暨董事變動達三分之一","clause":"第6款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：智新生技*（7832），2025-07-18 15:45，「公告本公司114年第一次股東臨時會獨立董事當選名單暨董事變動達三分之一」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7832-2025-07-18-1544-ub84r7","company_id":"7832","company":"智新生技*","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"15:44:23","subject":"公告本公司114年第一次股東臨時會重要決議事項","clause":"第15款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：智新生技*（7832），2025-07-18 15:44，「公告本公司114年第一次股東臨時會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7832-2025-07-18-1542-1roellr","company_id":"7832","company":"智新生技*","market":"興櫃","industry":"生技醫療","date":"2025-07-18","time":"15:42:57","subject":"公告本公司董事辭任","clause":"第6款","fact_date":"2025-07-18","cite_as":"公開資訊觀測站重大訊息：智新生技*（7832），2025-07-18 15:42，「公告本公司董事辭任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7803-2025-07-18-1510-4isxpt","company_id":"7803","company":"雲象科技-創","market":"上市","industry":"生技醫療","date":"2025-07-18","time":"15:10:23","subject":"公告本公司董事會通過會計主管任命案","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：雲象科技-創（7803），2025-07-18 15:10，「公告本公司董事會通過會計主管任命案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7803-2025-07-18-1510-u683hi","company_id":"7803","company":"雲象科技-創","market":"上市","industry":"生技醫療","date":"2025-07-18","time":"15:10:10","subject":"公告本公司董事會委任薪資報酬委員會成員","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：雲象科技-創（7803），2025-07-18 15:10，「公告本公司董事會委任薪資報酬委員會成員」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7803-2025-07-18-1509-o1u7dw","company_id":"7803","company":"雲象科技-創","market":"上市","industry":"生技醫療","date":"2025-07-18","time":"15:09:54","subject":"本公司董事會決議召開114年第二次股東臨時會相關事宜","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：雲象科技-創（7803），2025-07-18 15:09，「本公司董事會決議召開114年第二次股東臨時會相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2025-07-18-1447-8jn4a1","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2025-07-18","time":"14:47:28","subject":"本公司OBI-902 TROP2 ADC新藥獲台灣衛福部食藥署核准進行一/二期人體臨床試驗","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2025-07-18 14:47，「本公司OBI-902 TROP2 ADC新藥獲台灣衛福部食藥署核准進行一/二期人體臨床試驗」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2025-07-18-1335-szyhik","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2025-07-18","time":"13:35:09","subject":"本公司受邀參加由證券櫃檯買賣中心與元大證券聯合主辦之2025「臺灣生技產業高峰論壇」","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2025-07-18 13:35，「本公司受邀參加由證券櫃檯買賣中心與元大證券聯合主辦之2025「臺灣生技產業高峰論壇」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}